At a Glance
- Company: Cingulate
- Event: FDA rejection (CRL)
- Issue: Manufacturing-related deficiencies
- Focus area: ADHD treatment
- Next steps: Address issues and resubmit application
What happened?
Cingulate received a Complete Response Letter (CRL) from the US Food and Drug Administration, rejecting its application for a lead ADHD treatment due to manufacturing-related concerns. The decision delays potential approval of the drug.
Why does it matter?
Regulatory setbacks tied to manufacturing can be particularly disruptive because they often require additional validation, process changes or facility upgrades. Even if clinical data are strong, such issues can significantly delay time to market.
Who’s behind it?
Cingulate is a clinical-stage biopharmaceutical company developing treatments for attention deficit hyperactivity disorder (ADHD) using its proprietary drug delivery platform.
How was it achieved?
The FDA identified deficiencies related to manufacturing processes or controls rather than clinical efficacy or safety. This suggests the core drug profile may still be viable, but production standards must be improved to meet regulatory requirements.
What’s next?
Cingulate will need to address the FDA’s concerns, which could involve refining manufacturing processes, generating additional data or undergoing facility inspections. A resubmission timeline will depend on how quickly these issues can be resolved.